Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Expiratorisk muskelträning vid Parkinsons sjukdom med framåtböjd ryggstam

11 november 2026 uppdaterad av: Kateřina Dvořáková, General University Hospital, Prague

Effekten av expiratorisk muskelstyrketräning hos patienter med Parkinsons sjukdom och framåtlutad bål: en pilotstudie

Postural abnormalities (PA) negatively affecting the axial system are part of the symptoms of Parkinson's disease (PD). They occur in more than 20% of patients with PD especially in more advanced stages of the disease, contribute significantly to patient disability, affect respiratory functions, and reduce quality of life. Eighty-five percent of patients with forward trunk flexion (FTF) reported difficulties with swallowing (dysphagia), shortness of breath, and drooling. Previous studies in patients with PD also identified cough disorders (dystussia). Since cough and properly functioning swallowing are key mechanisms for airway protection, impairments in these functions lead to a higher risk of aspiration. The seriousness of this problem is clearly confirmed by the fact that aspiration pneumonia is the leading cause of death in patients with PD.

Among non-pharmacological interventions for airway protection, expiratory muscle strength training (EMST) has been shown to be beneficial in patients with PD. Recent randomized controlled studies demonstrated a significant effect of EMST on dysphagia, dystussia, drooling, and dysarthria in patients with PD.

However, the literature lacks data on the effect of EMST on dystussia in patients with PD and FTF, who, according to previous research, are also affected by restrictive ventilatory impairment, which negatively affects respiratory capacity and, in particular, cough strength.

The aim of this study is to evaluate the effect of EMST on cough, swallowing, respiratory muscle strength, and drooling in patients with PD and forward trunk flexion.

Studieöversikt

Status

Har inte rekryterat ännu

Betingelser

Studietyp

Interventionell

Inskrivning (Beräknad)

28

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

  • Namn: Martin Srp, PhD.
  • Telefonnummer: +420 224 965 513

Studieorter

      • Prague, Tjeckien, 12000
        • General University Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Diagnosis of Parkinson' s disease
  • Age ≥ 18 years
  • MoCA score (Montreal Cognitive Assessment) ≥ 19
  • Score II-IV during the "ON" phase under regular antiparkinsonian medication according to the Modified Hoehn and Yahr Scale
  • Pathological forward trunk flexion defined as thoracic (≥ 25°) or lumbar flexion (> 15°) during standing and walking, which completely disappears in the supine position (for the experimental group only)

Exclusion Criteria:

  • Change in antiparkinsonian medication within the last 3 months prior to study enrollment
  • Other neurological, orthopedic, cardiovascular, or respiratory comorbidities
  • Inability to cooperate due to neuropsychological dysfunction
  • Current smoking history
  • Inadequate lip seal

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Icke-randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: PD with Forward Trunk Flexion

Participants in this arm have Parkinson's disease and forward trunk flexion, defined as thoracic flexion ≥25° or lumbar flexion ≥15° while standing and walking, which completely disappears when lying down.

They will follow the study schedule including all assessments and the 4-week EMST program. Outcomes will include voluntary peak cough flow, respiratory muscle strength, swallowing function (FEES), drooling, and posture assessment using standardized photographs.

Participants will perform a 4-week Expiratory Muscle Strength Training (EMST) program using the EMST150™ device. EMST therapy sessions will be completed at home on 5 days per week, at the participant's convenience, performing five sets of five forceful exhalations through the device. The resistance of the device will be set to 75% of the patient's individual maximum expiratory pressure (MEP). The daily training will take approximately 15 minutes. Device resistance will be recalibrated at visits in weeks 0, 2, and 4 to ensure correct training and settings.

Aktiv komparator: PD without Forward Trunk Flexion

Participants in this arm have Parkinson's disease without forward trunk flexion (no postural abnormalities).

They will follow the same study schedule including all assessments and the 4-week EMST program as the experimental group.

Participants will perform a 4-week Expiratory Muscle Strength Training (EMST) program using the EMST150™ device. EMST therapy sessions will be completed at home on 5 days per week, at the participant's convenience, performing five sets of five forceful exhalations through the device. The resistance of the device will be set to 75% of the patient's individual maximum expiratory pressure (MEP). The daily training will take approximately 15 minutes. Device resistance will be recalibrated at visits in weeks 0, 2, and 4 to ensure correct training and settings.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Voluntary peak cough flow
Tidsram: Week -1, week 0, week 4, week 8

Assessments will be performed in accordance with American Thoracic Society/European Thoracic Society guidelines.

Week -1, week 0, week 4, week 8

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Assessment of Swallowing
Tidsram: Week -1, week 4, week 8

Swallowing will be assessed using a flexible endoscopic evaluation of swallowing (FEES). This is a standardized examination of the swallowing process, which involves transnasal insertion of a flexible endoscope into the pharynx, followed by evaluation of food passage. The assessment will be performed according to established protocols for patients with Parkinson's disease. All FEES examinations will be video-recorded, anonymized, and subsequently independently evaluated by blinded raters in a randomized order.

Week -1, week 4, week 8
Assessment of Drooling
Tidsram: Week -1, week 4, week 8

Drooling will be assessed using a questionnaire consisting of seven items evaluating the presence and severity of uncontrolled saliva leakage from the mouth in various aspects of daily life in patients with Parkinson's disease.

Week -1, week 4, week 8
Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP)
Tidsram: Week -1, week 0, week 4, week 8

Assessments will be performed in accordance with American Thoracic Society/European Thoracic Society guidelines.

Week -1, week 0, week 4, week 8
Forced vital capacity (FVC)
Tidsram: Week -1, week 0, week 4, week 8

Assessments will be performed in accordance with American Thoracic Society/European Thoracic Society guidelines.

Week -1, week 0, week 4, week 8
Forced expiratory volume (FEV1)
Tidsram: Week -1, week 0, week 4, week 8

Assessments will be performed in accordance with American Thoracic Society/European Thoracic Society guidelines.

Week -1, week 0, week 4, week 8
Peak expiratory flow (PEF)
Tidsram: Week -1, week 0, week 4, week 8

Assessments will be performed in accordance with American Thoracic Society/European Thoracic Society guidelines.

Week -1, week 0, week 4, week 8

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 februari 2027

Primärt slutförande (Beräknad)

1 april 2027

Avslutad studie (Beräknad)

1 juni 2027

Studieregistreringsdatum

Först inskickad

25 november 2025

Först inskickad som uppfyllde QC-kriterierna

25 november 2025

Första postat (Faktisk)

8 december 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

12 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

11 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera